Groupe Hospitalier Henri Mondor - Albert Chenevier

corporate_fareorganization

Groupe Hospitalier Henri Mondor - Albert Chenevier

- Funding / Projects
  (85)

85 Projects, page 1 of 17

RANDOMIZED PHASE II STUDY OF TWO ASSOCIATIONS OF RITUXIMAB AND CHEMOTHERAPY, WITH A PET-DRIVEN STRATEGY, IN PATIENTS FROM 18 TO 60 WITH DLBCL CD 20+ LYMPHOMA AND 2 OR 3 ADVERSE PROGNOSTIC FACTORS OF THE AGE-ADJUSTED IPI.
assignment_turned_inProjectPartners:Groupe Hospitalier Henri Mondor - Albert Chenevier, Centre Hospitalier Régional et Universitaire de Lille, HCL, CHLS, Hôpital le Bocage +1 partners
Groupe Hospitalier Henri Mondor - Albert Chenevier,
Centre Hospitalier Régional et Universitaire de Lille,
HCL,
CHLS,
Hôpital le Bocage,
Centre Henri Becquerel
Funder: Institut National du Cancer Project Code: INCa-DGOS-337
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Clinical phase II trial evaluating the efficacy of systemic Mesenchymal Stromal Cell (MSC) injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications (pelvic radiation disease, PRD) refractory to standard therapy. Acronym : PRISME (Pelvic Radiation dISease and MEsenchymal stromal cells)
assignment_turned_inProjectPartners:Centre René Gauducheau, Hôpital Saint-Antoine, Société Française de Bio Ingenierie Cellulaire et Tissulaire, Institut Gustave Roussy, Groupe Hospitalier Henri Mondor - Albert Chenevier +6 partners
Centre René Gauducheau,
Hôpital Saint-Antoine,
Société Française de Bio Ingenierie Cellulaire et Tissulaire,
Institut Gustave Roussy,
Groupe Hospitalier Henri Mondor - Albert Chenevier,
Institut de Radioprotection et de Sûreté Nucléaire,
Groupe Hospitalier Pitié Salpétrière,
Hôpital Européen Georges Pompidou (HEGP) - AP-HP,
Groupe Hospitalier Lariboisière - Fernand Widal,
Hôpital Saint-Louis,
U1018, INSERM, UPS, UVSQ Institut Gustave Roussy – B2M
Funder: Institut National du Cancer Project Code: INCa-DGOS-7278
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Radiation-induced sarcoma: predictive study based on the CONTICANET sarcomas registry.
assignment_turned_inProjectPartners:Centre Georges-François Leclerc, Groupe Hospitalier Henri Mondor - Albert Chenevier, Centre Paul Strauss, Centre Antoine Lacassagne, Institut de Cancérologie de Lorraine +5 partners
Centre Georges-François Leclerc,
Groupe Hospitalier Henri Mondor - Albert Chenevier,
Centre Paul Strauss,
Centre Antoine Lacassagne,
Institut de Cancérologie de Lorraine,
Centre Oscar Lambret,
Institut Gustave Roussy,
CHU Marseille - Hôpital la Timone,
Centre Léon Bérard,
INSERM U916
Funder: Institut National du Cancer Project Code: INCa-DGOS-3770
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant
assignment_turned_inProjectPartners:HUG, Groupe Hospitalier Henri Mondor - Albert Chenevier, CHU, Hôpital Claude Huriez, CHRU MTP +10 partners
HUG,
Groupe Hospitalier Henri Mondor - Albert Chenevier,
CHU,
Hôpital Claude Huriez,
CHRU MTP,
Hôpital Necker- Enfants malades,
Centre Hospitalier Universitaire de Limoges,
CHU Nantes - Hôtel Dieu,
Centre Hospitalier Universitaire de Poitiers,
Centre Hospitalier Universitaire de Toulouse,
Institut de cancérologie Lucien Neuwirth,
Institut Paoli-Calmettes- (IPC),
HUS,
HCL,
Groupe Hospitalier Pitié Salpétrière
Funder: Institut National du Cancer Project Code: INCa-DGOS-11089
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Grief of cancer patients' spouses: evaluation and subjective experience.
assignment_turned_inProject2011 - 2013Partners:Groupe Hospitalier Henri Mondor - Albert Chenevier, UNIVERSITE RENE DESCARTES PARIS 5, Institut Curie
Groupe Hospitalier Henri Mondor - Albert Chenevier,
UNIVERSITE RENE DESCARTES PARIS 5,
Institut Curie
Funder: Institut National du Cancer Project Code: INCa-4699
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu

chevron_left
1
2
3
4
5
chevron_right

Groupe Hospitalier Henri Mondor - Albert Chenevier

Groupe Hospitalier Henri Mondor - Albert Chenevier

85 Projects, page 1 of 17

RANDOMIZED PHASE II STUDY OF TWO ASSOCIATIONS OF RITUXIMAB AND CHEMOTHERAPY, WITH A PET-DRIVEN STRATEGY, IN PATIENTS FROM 18 TO 60 WITH DLBCL CD 20+ LYMPHOMA AND 2 OR 3 ADVERSE PROGNOSTIC FACTORS OF THE AGE-ADJUSTED IPI.

Radiation-induced sarcoma: predictive study based on the CONTICANET sarcomas registry.

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant

Grief of cancer patients' spouses: evaluation and subjective experience.

Loading